News for Biophytis SA (0D1W.L)

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced t...

Biophytis SA (BPTSY) Tuesday unveiled its strategic outlook for the year and said that 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 (20-Hydroxyecdysone) and its commercialization.

H.C. Wainwright optimistic on Biophytis stock as Phase 2 trial approved

Press release Biophytis Announces Transfer of ADSs to OTC Market ADSs delisted from Nasdaq, which will result in meaningful...

Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals.

Biophytis / Key word(s): Miscellaneous Biophytis presented its phase 3 protocol in the treatment of sarcopenia 22-March-2024...

Biophytis announces its participation in several conferences in Europe and the US during the first quarter of 2024 Paris and Cambridge , December 11, 2023 - 07am CET -...

Biophytis / Key word(s): Miscellaneous/Miscellaneous Biophytis receives notice of delisting from Nasdaq and announces it wil...

French public limited company with a Board of Directors with share capital of €4,267,706.99 Registered office: 14 Avenue de l'Opéra - 75001 PARIS Paris Commercial Register ...

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid...

Clinical-stage biotechnology company, Biophytis SA (BPTS) and SEQENS concluded a master agreement for the production of the active compound in Sarconeos ((BIO101)), Biophytis' main...